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SUMMARY
Fibromyalgia (FM) is a clinical syndrome commonly observed in daily medical prac-
tice and its etiopathogenesis is still unclear. As it is characterized by chronic musculo-
skeletal pain associated with several symptoms, FM may be confused with several other 
rheumatic and nonrheumatic diseases when they course with pictures of diffuse pain 
and chronic fatigue. FM treatment should be multidisciplinary, individualized, count on 
active participation of the patient, and based on combined pharmacological and non-
pharmacological modalities. It is found both in work and non-work settings, and there is 
no scientific evidence in the literature showing that FM might be caused by occupation. 
FM seldom leads to incapacity to work. In cases where pain or fatigue do not respond 
to appropriate treatment, reaching significant levels, a short period away from work can 
be considered. As FM is a relevant subject, this review article was based on exploratory, 
qualitative and bibliographic investigation, aiming to study the main clinical and oc-
cupational aspects of FM, emphasizing the theoretical-conceptual background and the 
experience of specialists.
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INTRODUCTION
Fibromyalgia (FM) can be described as a painful clinical 
syndrome associated with other symptoms, and it is also 
termed fibromyalgia syndrome. In this review, the term 
fibromyalgia, used in the International Classification of 
Diseases (ICD), has been adopted. 
Although it has been recognized for a long time, FM 
has been seriously studied for the last four decades. FM 
was not considered a well-defined clinical entity until the 
1970’s, when the first reports on sleep disturbances were 
published. The concept of FM was introduced in 1977, 
when anatomical sites with excessive pain sensitivity 
were described; they were termed tender points. Sleep 
disturbances, including those experimentally induced, 
were also documented, possibly reproducing pain and 
muscular sensitivity symptoms seen in this chronic pain 
syndrome1.
The term fibromyalgia is derived from the Latin word 
fibro (fibrous tissue, present in ligaments, tendons and 
fasciae) and from the Greek words mio (muscular tissue), 
algos (pain), and ia (condition). It was first proposed by 
Yunun et al. in 1981, aiming to replace the term fibrosi-
tis2, hitherto used to name a particular type of rheuma-
tism characterized by the presence of tender indurated 
muscular points, which were understood as having no 
tissue inflammation3.
In the 1980’s, several diagnostic criteria based on sys-
temic disease exclusion, presence of certain symptoms, 
and tender points on physical examination were suggested.
In 1990, a committee from the American College of 
Rheumatology (ACR) defined the FM classification cri-
teria as the presence of a clinical history of widespread 
pain, affecting the axial and peripheral skeleton, above 
and below the waist, and with a duration > 3 months; 
physical examination pain elicited by application of a 
4 kg/cm2 force to at least 11 of the following 18 tender 
points (9 pairs): 1) suboccipital muscle insertions; 2) liga-
ments of intertransverse spaces C5-C7; 3) trapezius up-
per border; 4) supraspinatus muscle origins; 5) pectoral 
muscle junction with the second rib costocondral junc-
tion; 6) 2 cm distal to the elbow lateral epicondyle; 7) up-
per outer quadrant of buttocks, below the iliac spine; 8) 
muscle insertions at the femoral trochanter; 9) fat pad, 
slightly above the knee midline4.
The current diagnostic criteria do not include tender 
points; however, they consider symptoms not related to 
the locomotor system. In addition to musculoskeletal 
pain, they assess the syndrome’s severity and are useful to 
establish the diagnosis5.
Considering the subject’s relevance, this review aims 
to discuss the main clinical and occupational aspects of 
FM.
METHODS
This review article is derived from a qualitative, explor-
atory and bibliographic investigation performed in the 
electronic libraries SciELO and PubMed, emphasizing 
the theoretical-conceptual background and the experi-
ence of specialists. The keywords “fibromyalgia”, “review”, 
“rheumatology”, “occupational medicine”, and “referred 
pain” were searched. Moreover, a manual search of refer-
ences from selected articles was performed so that papers 
not mentioned in the databases could be found. The ref-
erences contributing to meet the search target, i.e., re-
view of the main clinical and occupational aspects of FM, 
were selected from the material retrieved. The investiga-
tion was closed only when signs of search theme theoreti-
cal saturation were found.
EPIDEMIOLOGY
FM occurs at any age and is much more often diagnosed 
in females. A study conducted by the American College 
of Rheumatology found an FM prevalence of 3.4% for fe-
males and 0.5% for males, with an estimated prevalence of 
2% for both genders6.
The first studies dedicated to FM prevalence were re-
ported in the 1980’s, but the diagnostic criteria were differ-
ent, albeit similar to the current criteria. The results ranged 
from 2.1% in private practices, 5.7% in outpatient facili-
ties, 5% to 8% for inpatients, and as high as 14% to 20% in 
rheumatology outpatient settings7.
A Brazilian study determined a prevalence of 2.5% in 
the population, with the majority of cases identified in fe-
males, of whom 40.8% were aged 35 to 44 years8. In some 
European countries, FM rates found in the adult popula-
tion were as high as 10.5%9.
FM is a condition commonly seen in daily clinical 
practice and one of the main causes for medical visits 
linked to the musculoskeletal system; it is considered the 
second main rheumatologic disorder, surpassed only by 
osteoarthritis10.
Despite the good prognosis for this painful condition, 
patients with FM consume huge amounts of financial re-
sources in public or private health care both for treatment 
and diagnostic investigation.
The magnitude of economic and financial impact of 
FM on society is evidenced in an American study reported 
in 2007, finding an annual cost of USD 9,573 per patient, 
and representing an expenditure three to five times higher 
than that of the general population11.
Likewise, a survey conducted in the Netherlands identi-
fied a mean annual cost of € 7,813 per patient with FM, € 
8,553 for chronic low back pain, and € 3,205 for ankylosing 
spondylitis – the latter amount was calculated before biolog-
ics were approved for ankylosing spondylitis treatment12.
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Assuming that FM affects 3% of the population, ac-
cording to statistical data, and using data from demo-
graphical studies, these estimates can be translated into 
an incremental annual cost of about €12 billion for a 
population of 80 million, with € 960 million (8%) repre-
senting the costs of drug therapy13.
ETIOPATHOGENESIS
FM etiology and pathophysiology are still nuclear. The 
current hypotheses focus on the central mechanisms of 
pain modulation and amplification in the genesis of FM. 
A pathophysiological model integrating many of the ideas 
found in literature has been accepted; it suggests that the 
primary disorder in FM would be a change in some cen-
tral mechanism of pain control, possibly resulting from 
a neurotransmitter dysfunction. Such neurohormonal 
dysfunction would include either an inhibitory neu-
rotransmitter deficiency in spinal or supraspinal levels 
(serotonin, enkephalin, norepinephrine, and others) or 
an excitatory neurotransmitter hyperactivity (substance 
P, glutamate, bradykinin, and other peptides). Both con-
ditions might be present. These dysfunctions could be 
genetically predetermined and triggered by a nonspecific 
stress, such as a viral infection, psychological stress, or 
physical trauma14.
The hypothalamic-pituitary-adrenal axis and the 
sympathetic nervous system, comprising the main sys-
tems of stress response along with their interactions 
with neurohormonal dysfunctions, are also implicated in 
the pathophysiology. Susceptibility to FM development 
seems to be influenced by environmental, hormonal, 
and genetic factors15,16, causing changes at the neurohor-
monal receptors level. An acute stressor could trigger the 
development of a disordered hypothalamic-pituitary-ad-
renal axis through unclear mechanisms, possibly involv-
ing the sympathetic nervous system and the serotonergic 
system. Thus, the hypothalamic-pituitary-adrenal axis is 
believed to play a role in mediating and perpetuating FM 
symptoms17.
DIAGNOSIS
FM diagnosis is notably clinical5. In addition to diffuse 
pain in skeletal muscle and the physical examination 
finding of multiple tender points, most patients with FM 
also report fatigue, muscle stiffness, pain after exertion, 
and sleep disturbances. Symptoms of depression, anxi-
ety, memory deficit, inattention, tension headache or mi-
graine, dizziness, vertigo, tingling, symptoms consistent 
with irritable bowel syndrome or restless feet syndrome, 
are among several other symptoms not related to the lo-
comotor system18. Generalized chronic pain, however, is 
a cardinal symptom. Myalgia may often show a migra-
tory characteristic responding to biomechanical stress or 
trauma19.
Despite having too low diagnostic accuracy to be con-
sidered classification criteria, sleep disturbances occur in 
up to 100% of patients with fibromyalgia and are highly 
variable. Sleep disturbances are characterized by difficul-
ty in sleep induction, too many awakenings during the 
night, and a sense that the sleep is not restorative. Sleep 
disturbances evoke adverse consequences, such as cog-
nitive deficits, morning tiredness, and tendency towards 
triggering psychiatric disorders20,21.
The psychological profile of patients with fibromy-
algia is associated with perfectionism, severe self-crit-
icism, and obsessive search for details22. The high de-
pression prevalence among patients with fibromyalgia is 
noteworthy23-25.
Depression characteristics, such as fatigue, guilt feel-
ings, low self-esteem, and victimization lead to a symp-
tom flare and impair the patient’s coping strategies to-
ward the disease26.
So far, there are no specific laboratory tests to confirm 
the FM diagnosis. The patients have normal inflamma-
tory activity tests and imaging studies27.
DIFFERENTIAL DIAGNOSIS
FM may be confused with several other diseases when 
they course with diffuse pain pictures and chronic fatigue.
The patient with hypothyroidism can have a clinical 
picture mimicking FM. Thus, as these patients are ap-
proached, thyroid function assays are recommended. 
The literature describes FM clinical picture as an initial 
manifestation of hypothyroidism28. However, there is no 
evidence that stabilizing thyroid function would dispel 
the FM picture, and there is no evidence that most pa-
tients with FM have a thyroid dysfunction.
Another hormone disorder possibly causing diagnos-
tic confusion with FM is primary hyperparathyroidism. 
This disorder results from a parathyroid adenoma (mono-
clonal origin) in 80% to 90% of cases. In nearly all remain-
ing cases, it results from hyperplasia in the four parathy-
roids (polyclonal origin). In addition to bone (bone pain, 
pathological fractures, cortical osteopenia, bone cysts, and 
osteitis fibrosa cystica) and kidney (renal colic, nephroli-
thiasis, and nephrocalcinosis with kidney failure) manifes-
tations, which are classically part of the disease, unspecific 
symptoms, such as fatigue, emotional disorder, neuropsy-
chiatric abnormalities and muscular aches may be present, 
mimicking the clinical picture of FM29.
Vitamin D deficiency with secondary hyperparathy-
roidism may cause bone and muscular pain sometimes 
misinterpreted as FM30.
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In certain settings, osteomalacia can be part of dif-
ferential diagnosis, as a number of patients have an on-
set with weakness, muscular pain, and bone tenderness 
before the radiologic and metabolic manifestations are 
seen31. Polymyalgia rheumatica is another condition that 
must be remembered in FM differential diagnosis, de-
spite the typical involvement of the pelvic and scapular 
girdles and the significant elevation of erythrocyte sedi-
mentation rate32. The fact that patients with polymyal-
gia rheumatica have a satisfactory and rapid response to 
low-dose oral corticosteroids can contribute to diagnos-
tic elucidation. However, muscular ache, the predomi-
nant characteristic in this illness, might confuse a less 
attentive practitioner, particularly when muscular ache 
is diffuse.
In some cases, polymyositis (as well as other myositis) 
may be confused with FM. In this disease, it is important 
to remember that the main complaint is weakness rather 
than muscular pain. This weakness is characteristically 
insidious, symmetrical, and progressive, particularly at 
the scapular and pelvic girdles. It is painful in approxi-
mately 15% to 30% of cases. Patients may have arthral-
gia, similar to FM patients. Other clinical manifestations 
of muscular inflammatory disease, along with laboratory 
abnormalities, particularly high muscle enzymes, lead to 
the correct diagnosis33.
Some autoimmune collagen diseases, particularly 
rheumatoid arthritis and systemic lupus erythemato-
sus, may initially manifest as diffuse pain and fatigue, 
leading to FM misdiagnosis. In other situations, patients 
with established rheumatoid arthritis or systemic lupus 
erythematosus, with the various clinical and laboratory 
manifestations of these illnesses, may simultaneously 
present with a FM clinical picture. Despite the appro-
priate therapeutic response of the inflammation, painful 
complaints may remain. In these cases, synovitis disap-
pears and inflammatory activity tests are normalized, 
with the concomitant maintenance of a FM clinical pic-
ture, coursing independently of the underlying disease. 
In one study, fibromyalgia coexistence was found in 12% 
of patients with rheumatoid arthritis34. Not infrequently, 
Sjögren syndrome may have, as an initial manifestation, 
symptoms of diffuse and unspecific muscle pain accom-
panied by tiredness, making the diagnosis more difficult 
until laboratory parameters and other clinical character-
istics are established35.
Certain adverse reactions to drugs may cause diffuse 
myalgia, thus confusing clinical follow-up. Among these 
drugs, H2 receptor blocking agents (used in peptic dis-
ease), fibrates, and statins (used in the treatment of dys-
lipidemia)36 should be mentioned. Illicit drug users may 
experience similar reactions to a FM clinical picture, 
particularly patients using cocaine and Cannabis. Pa-
tients with a history of alcoholism may also have muscle 
pain during either the alcohol abuse period or the with-
drawal period37.
Certain infections, in particular hepatitis C, human 
immunodeficiency virus (HIV), and Lyme disease, may 
cause diffuse muscular pain, making diagnosis more dif-
ficult, mainly when fever and other signs are not found38. 
Serum analysis can contribute to elucidate some cases.
Patients who underwent long-term corticosteroid 
therapy, irrespective of the reason, can experience cor-
ticosteroid withdrawal, particularly if the drug cessation 
has been abrupt or inappropriate. These patients can ex-
perience diffuse muscle pain, rapidly responding to cor-
ticosteroid reintroduction39.
Another condition that must be accounted for in FM 
differential diagnosis is paraneoplastic syndrome. Obvi-
ously, there are other signs directing the correct clinical 
reasoning in this picture. However, in rare situations, a 
paraneoplasm may manifest with a clinical picture simi-
lar to FM and issue an important diagnostic challenge, 
particularly in the case of bronchogenic carcinoma40.
Chronic fatigue syndrome should also be included 
into the differential diagnosis. Low fever or recurring 
pharyngitis history, in addition to lymphadenopathy, 
can contribute to clarify the diagnosis. In chronic fatigue 
syndrome, tiredness predominates, while diffuse pain 
predominates in fibromyalgia41.
Possibly the greatest diagnostic challenge is differ-
entiating FM from psychogenic rheumatism. In certain 
situations, the patient’s clinical picture purely expresses 
a psychiatric disorder, particularly depression. Depres-
sion is known to occur more commonly in fibromyal-
gia than in controls or even in patients with rheuma-
toid arthritis42. About half of patients with FM have had 
a depression episode at some time in their lives. Many 
depression symptoms, such as tiredness, energy loss, 
discouragement, and sleep disturbances, are identical to 
those in FM. Maybe this is why many authors consider 
fibromyalgia as a depression manifestation. However, it 
is important to keep in mind that a large number of pa-
tients with fibromyalgia have neither depression nor any 
other psychiatric disorder component43.
It is also important to note that sometimes patients 
with fibromyalgia have been misdiagnosed as having 
RSI/WRMD (repetition strain injury/work-related mus-
culoskeletal disorders). In an investigation conducted 
in the Discipline of Rheumatology at Escola Paulista de 
Medicina, 103 patients with an initial diagnosis of rep-
etition strain injury (RSI) or work-related musculoskel-
etal disorder (WRMD), all of them involved in a labor 
dispute, were studied. Among these 103 patients, 73 
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were found to meet diagnostic criteria for FM and they 
had no evidence of tissue injury44.
Finally, RSI and WRMD cannot be widely pointed 
out as a disease, but they are acronyms embodying a het-
erogeneous group of musculoskeletal disorders having 
a work agent as one of the required causes for their ap-
pearance. It is important to point out that FM is not a 
RSI or a WRMD.
TREATMENT
To this day, the lack of knowledge about FM etiopatho-
genesis prevents a totally effective treatment.
FM treatment should be multidisciplinary, individu-
alized, count on the patient’s active participation, based 
on combined non-pharmacological and pharmacological 
therapy and should be designed according to the inten-
sity and characteristics of symptoms. It is important that 
biopsychosocial issues involved in the context of illness 
are also considered.
As an initial part of treatment, patients are provided 
with basic information about FM and treatment options, 
and are instructed about pain control and self-control 
programs.
FM drug therapy, in addition to pain control, aims to 
induce a better quality sleep and treat associated symp-
toms, such as depression and anxiety.
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
should not be used as first-line drugs in patients with 
FM45. Although there is no evidence of inflammation, 
NSAIDs used in treating more prominent painful com-
plaints act satisfactorily on FM-associated symptoms, 
such as headache and joint pain46.
Corticosteroids are not a part of the therapeutic re-
sources used in FM47.
In Brazil, two out of three drugs approved by the Food 
and Drug Administration (FDA) to treat FM are avail-
able: pregabalin and duloxetine. Pregabalin is a calcium 
channel modulating agent, reducing the release of excit-
atory pain neurotransmitter release at nervous endings, 
particularly substance P and glutamate. Studies show 
significant relief of pain, fatigue, anxiety, and sleep dis-
turbances by using this drug48. Duloxetine is a serotonin 
and noradrenalin reuptake inhibitor that also has shown 
to be effective in reducing pain and improving functional 
capacity in FM regardless of the presence of depression49.
Tricyclic antidepressants, especially amitriptylin 
and cyclobenzaprine, ingested two to three hours be-
fore bedtime, can be effective in decreasing the pain and 
improving the sleep, as well as enhancing the functional 
capacity50,51.
Many other drugs were studied, but the results were 
usually less satisfactory52.
Non-pharmacological treatment has a crucial role in 
managing FM symptoms53.
FM patients benefit from physical activity. Several 
reasons justify the encouragement of physical activity in 
this syndrome: increased levels of serotonin and other 
inhibitory neurotransmitters; increased GH (growth 
hormone) production; hypothalamic-pituitary-adrenal 
axis and autonomous nervous system regulation; in-
creased capillary density; increased myoglobin count; 
and increased mitochondrial activity. All these changes 
contribute to improve pain, quality of sleep, fatigue, 
anxiety, and other symptoms. The possibility of social-
ization, depending on the circumstances, and the posi-
tive influence on some psychological aspects should 
also be taken into account. Physical activity has repre-
sented the most frequently employed and studied non-
drug intervention for FM. However, the most appropri-
ate type has not been established, as well as the optimal 
frequency and intensity48.
Psychological aspects should always be evaluated 
and occasional disorders should be identified, aiming 
at real support and specialized help as necessary. Sleep 
disturbances should also be approached and treated54.
In a recent literature review, involving mainly system-
atic reviews and meta-analysis publications over last 12 
years, a lack of uniformity on the type of rehabilitation 
and exercise that should be employed in this chronic 
pain syndrome was verified. The forms of aerobic activity 
studied (walking, marching, cycling, rowing, etc.) were 
varied, as well as other types of exercising (stretching, 
isometric and isokinetic exercises, among other exer-
cises for muscular strengthening), and various forms of 
hydrotherapy (aquatic respiratory exercises, deep water 
running, hydrogymnastics, swimming, among others). 
A great diversity in rehabilitation methods, such as cop-
ing, biofeedback, family education, cognitive-behavioral 
therapy, and manipulation and relaxation techniques was 
also found. Overall, the studies concluded that the effects 
were beneficial both from exercises and from different 
types of rehabilitation, even if involving heterogeneous 
modalities48.
OCCUPATIONAL ASPECTS
Scientific literature offers no evidence that FM is occu-
pational in origin. In the 1990’s, some scientific papers 
related to occupational trauma and litigation involving 
FM were published55-57.
However, literature data are not enough to establish 
causality. The connection with repetition microtrauma 
has been suggested by some authors; however, these stud-
ies were either conducted with small samples of patients 
or documented with isolated case reports58,59.
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FM does not usually lead to incapacity to work. In cas-
es of significant pain or fatigue, taking a few sick days can 
be considered. Nevertheless, litigious repetitive requests 
of temporary leaves have been observed in judicial prac-
tice, resulting in a long and continued abscence of the pa-
tient. There is no systematic investigation of these lawsuits 
aiming to quantify how often this has occurred or how 
its economic dimension has impacted the social security 
system in Brazil. Data are empirical and observational. It 
cannot be denied that a protracted leave and the search 
for financial compensation in a chronic pain setting may 
be harmful, as investigations have demonstrated60,61.
Of note, individuals with chronic pain are prone 
to persistence of painful symptomatology when they 
are involved in litigation62. In addition, there is in-
creased malingering in a permissive system of judicial 
compensation63,64.
It is debatable whether patients with fibromyalgia 
experience their symptoms worsened when their func-
tions are performed under strict productivity criteria and 
pressured by time, such as in assembly lines. To date, the 
biomechanical limits of these patients have not been ob-
jectively defined, making it impossible to establish reduc-
tion, modification, or elimination criteria for any specific 
work setting. A worker with FM might keep performing 
his/her work, more slowly, with his/her productivity cri-
teria or demands reconsidered.
Systematic reviews, such as that by Boocock et al., 
also establish that there is no current specific modifica-
tion in work or labor intervention strategy that can be 
considered effective to solve the occupational issues in-
volving these patients. The authors also mention the lack 
of research for several labor activities65.
In FM, as in any other chronic pain syndrome, the 
sense of incapacity can be influenced by social and psycho-
logical factors. Work incapacity allegations may be vicious 
when psychological factors are predominant, or when pain 
or fatigue seems less severe than reported. The problem 
can become more pronounced when there is an interest 
in secondary gain. In settings where ensuring the absence 
of such interest is difficult to prove, the only solution is to 
keep a prolonged longitudinal follow-up, which improves 
doctor-patient relationship.
It is important to note that courts in the United States 
usually do not grant benefits to patients with FM66.
These patients are prone to have their symptoms wors-
ened when they present with associated psychological 
disorders. A study conducted in Brazil found that 30% of 
FM patients exhibited severe depression and 34%, moder-
ate depression; this same study found that 70% of FM pa-
tients had traits of significant anxiety and 88% exhibited a 
high anxiety status67.
Concerning depression, Brazilian labor laws have spe-
cific terms for this illness. However, it is imperative not to 
confuse depression with FM. A physician should not at-
tempt to diagnose depression without having enough ex-
perience and without well-established diagnostic criteria.
If there is a significant level of depression, the possi-
bility of a medical leave should be considered. However, 
the patient must not feel comfortable in this situation, 
due to the consequent creation of a vicious circle and no 
adherence to treatment.
Another noteworthy aspect is the possibility of ma-
lingering. In a controlled study involving FM patients, 
healthy controls and patients motivated to malinger, the 
American College of Rheumatology (ACR) criteria were 
found to be 80% accurate, with a good agreement and 
reproducibility level towards tender points and control 
points so as to distinguish malingerers. This study’s re-
sults demonstrate that there is no malingering test and 
it is likely a number of malingerers and true FM patients 
could remain unidentified68.
FINAL CONSIDERATIONS
FM is a syndrome with a prominently clinical diagnosis, 
characterized by chronic musculoskeletal pain associated 
with various symptoms. It may be confused with several 
rheumatic and non-rheumatic diseases. An individual-
ized and multidisciplinary approach, combining drug 
and nondrug treatment, is required.
There is no scientific evidence determining that FM is 
caused by work. However, reasonable labor adaptations 
should be sought, including reduced time for task execu-
tion, among others, although labor modifications for this 
disease are not yet defined.
If the patient with fibromyalgia presents significant 
levels of pain or fatigue and does not respond to appro-
priate treatment, a short medical leave could be consid-
ered, although repetitive temporary leaves obtained by 
litigious means have been empirically observed, but they 
have no scientific support for their real requirement and 
their consequent economic repercussions. There is nega-
tive evidence for patients regarding litigation and long 
leaves. Prolonged leaves are justified in the case of associ-
ated severe depression.
When approaching patients with fibromyalgia, it is 
important to explain this chronic pain syndrome and the 
barriers against clinical improvement.
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